share_log

BRIEF-Precigen Receives FDA Orphan Drug Designation For Prgn-2012 Adenoverse Immunotherapy In Patients With Recurrent Respirato

路透社 ·  Mar 18, 2021 20:55
March 18 (Reuters) - Precigen Inc :
   * PRECIGEN RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PRGN-2012 ADENOVERSE™ IMMUNOTHERAPY IN PATIENTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP)

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment